Viking Therapeutics

197 articles about Viking Therapeutics

• Viking Therapeutics to Participate at Upcoming Investor Conferences - September 7, 2023

  9/7/2023

  Viking Therapeutics, Inc. today announced that the company will participate at two upcoming investor conferences. 

• Viking Therapeutics Announces Initiation of Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity

  9/6/2023

  Viking Therapeutics, Inc. announced the initiation of a Phase 2 clinical trial of VK2735, the company's wholly-owned dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors.

• Viking Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

  7/26/2023

  Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the second quarter and six months ended June 30, 2023, and provided an update on its clinical pipeline and other corporate developments.

• Viking Therapeutics to Report Financial Results for Second Quarter 2023 on July 26, 2023

  7/19/2023

  Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX) announced today that the company will release financial results for the second quarter 2023 after the market close on Wednesday, July 26, 2023.

• Ligand’s Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)

  5/16/2023

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX) today announced positive top-line results from its Phase 2b clinical trial of VK2809, a novel liver-selective thyroid hormone receptor beta agonist, in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH).

• Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)

  5/16/2023

  Viking Therapeutics, Inc. today announced positive top-line results from its Phase 2b clinical trial of VK2809, the company's novel liver-selective thyroid hormone receptor beta agonist, in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH).

• 

  Viking Therapeutics Clears Mid-Stage NASH Trial

  5/16/2023

  Results from Phase IIb VOYAGE study showed Viking’s oral thyroid beta receptor agonist cut liver fat content by up to 51% in confirmed non-alcoholic steatohepatitis patients.

• Viking Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

  4/26/2023

  Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX) today announced its financial results for the first quarter ended March 31, 2023, and provided an update on its clinical pipeline and other corporate developments.

• Viking Therapeutics to Report Financial Results for First Quarter 2023 on April 26, 2023

  4/20/2023

  Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX) announced today that the company will release financial results for the first quarter 2023, after the market close on Wednesday, April 26, 2023.

• Viking Therapeutics to Present at 22nd Annual Needham Healthcare Conference

  4/11/2023

  Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX) today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation as part of the 22nd Annual Needham Healthcare Conference.

• Viking Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Underwriters' Option to Purchase Additional Shares

  4/3/2023

  Viking Therapeutics, Inc. announced the closing of its previously announced underwritten public offering of 19,828,300 shares of its common stock at a public offering price of $14.50 per share, which includes the exercise in full by the underwriters of their option to purchase up to 2,586,300 additional shares of common stock.

• Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock

  3/30/2023

  Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced the pricing of its underwritten public offering of 17,242,000 shares of its common stock at a price to the public of $14.50 per share.

• 

  Viking Enters Weight-Loss Arena with Promising Phase I Data

  3/29/2023

  Tuesday, Viking Therapeutics released Phase I results for its weight-loss candidate VK2735, which demonstrated a good safety and tolerability profile and resulted in significant weight reductions.

• Viking Therapeutics Announces Proposed Public Offering of Common Stock - March 29, 2023

  3/29/2023

  Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced that it intends to offer and sell shares of its common stock in an underwritten public offering.

• Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735

  3/28/2023

  Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced positive results from the company's Phase 1 single ascending dose and multiple ascending dose clinical trial of VK2735.

• Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Oral Formulation of Dual GLP-1/GIP Receptor Agonist VK2735

  3/28/2023

  Viking Therapeutics, Inc. today announced that it has initiated a Phase 1 clinical study to evaluate a novel oral formulation of the company's dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist VK2735.

• Viking Therapeutics to Participate at Upcoming Investor Conferences - March 7, 2023

  3/7/2023

  Viking Therapeutics, Inc. today announced that the company will participate at two upcoming investor conferences. 

• Viking Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

  2/8/2023

  Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX) today announced its financial results for the fourth quarter and year ended December 31, 2022, and provided an update on its clinical pipeline and other corporate developments.

• Viking Therapeutics to Present at SVB Securities Global Biopharma Conference

  2/7/2023

  Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation as part of the SVB Securities Global Biopharma Conference.

• Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2022 on February 8, 2023

  2/1/2023

  Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced that the company will release financial results for the fourth quarter and year-end 2022, after the market close on Wednesday, February 8, 2023.